Aim: Chylothorax is a rare but life-threatening condition in newborns. Octreotide, a somatostatin analogue, is widely used as a therapeutic option in neonates with congenital and acquired chylothorax, but its therapeutic role has not been clarified yet. Methods: We performed a systematic review to assess the efficacy and safety of octreotide in the treatment of congenital and acquired chylothorax in newborns. Comprehensive research, updated till 31 October 2017, was performed by searching in PubMed, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) databases using the MeSH terms 'octreotide' and 'chylothorax'. Both term and preterm newborns with congenital or acquired chylothorax treated with octreotide within the 30th day of life were included. Octreotide treatment was considered effective if a progressive reduction/ceasing in drained chylous effusion occurred. Results: A total of 39 articles were included. Octreotide was effective in 47% of patients, with a slight but not significant difference between congenital (30/57; 53.3%) and acquired (9/27; 33.3%) chylothorax (P = 0.10). Marked variation in octreotide regimen was observed. The most common therapeutic scheme was intravenous infusion at a starting dose of 1 μg/kg/h, gradually increasing to 10 μg/kg/h according to the therapeutic response. Side effects were reported in 12 of 84 patients (14.3%). Only case reports were included in this review due to the lack of randomised controlled trials. Conclusion: Octreotide is a relatively effective and safe treatment option in neonates with chylothorax, especially for the congenital forms.
1 Although rare, both congenital and acquired chylothorax remain a serious and potentially life-threatening disease in newborns. 2 No agreement on the optimal treatment has been reached to date. 3 The use of octreotide in the conservative management of chylothorax in infants has been suggested, but no clear indications on its efficacy, safety and optimal regimen have been identified, and no consistent recommendation on its use was reached.
What this paper adds
1 We report the result of a systematic review to assess the efficacy and safety of octreotide in the treatment of congenital and acquired chylothorax in newborns. 2 Octreotide is a relatively effective and safe treatment option in neonates with chylothorax, especially for the congenital forms. 3 This systematic review suggests that octreotide therapy should be considered an adjunctive treatment in term and preterm neonates affected by congenital and acquired chylothorax.
Chylothorax results from the accumulation of lymphatic fluid within the pleural space as a consequence of obstruction or leakage of the thoracic duct or one of its contributories. 1 The diagnosis is made in the presence of pleural effusion with a milk-like appearance, a triglyceride level >1.1 mmol/L and a total cell count >1000 cells/mL with >80% lymphocytes. 2 Although chylothorax demonstrates low prevalence in the neonatal population, occurring with an incidence of 1:15 000, 3 the mortality associated with this condition remains high, ranging from 15 to 57%, particularly when hydrops fetalis coexists. 4, 5 Congenital chylothorax is caused by intrinsic abnormalities of the lymphatic system, 2, 6 while the acquired form is usually secondary to the rupture of the thoracic duct as a complication of cardiac and thoracic surgery. 7 Once the diagnosis is established, the first-line management of chylothorax consists of pleural drainage and dietary modification, ranging from total parenteral nutrition to median-chain triglyceride-enriched formulas. 8 Octreotide, a somatostatin analogue, is currently used as an additional treatment in neonatal congenital and postoperative chylothorax, 9 despite no consensus being reached on its use due to the lack of evidences about its efficacy and safety. 10 We conducted a systematic review to assess the efficacy and the safety of octreotide in newborns affected by congenital or acquired chylothorax.
Methods
We performed a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations 11 ( Fig. 1) . A comprehensive research using the MeSH terms 'octreotide' and 'chylothorax' was carried out in PubMed, MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials databases until 31 October 2017, with articles published in English only. Animal studies were excluded. Four reviewers (C Bellini, R Cabano, LC De Angelis and T Bellini) screened all titles and abstracts independently. Subsequent full-text screening for eligibility was conducted for all potentially relevant articles. Both premature and term neonates with congenital or acquired chylothorax receiving octreotide within the 30th day of life were considered eligible. Patients treated with somatostatin were excluded from our analysis. Quality rating of the included studies was performed. 12 Discrepancies in study selection and rating were resolved through discussion. Treatment was considered effective if a progressive reduction/ceasing in drained chylous effusion was described, irrespective of duration of the treatment. If not clearly specified in the text, we considered octreotide effective according to author's judgement. In case of inadequate information, authors were contacted to clarify or provide additional information. Data were described as absolute and relative frequencies for categorical variables, while means, standard deviation (SD), medians and range were used for continuous variables. Categorical data were compared by chi-square or by Fisher's exact test. The Kolmogorov-Smirnov test was used to investigate the normal distribution of the variables. The Mann-Whitney U-test was appropriately applied to analyse the continuous data. A P value of less than 0.05 was considered statistically significant. Statistical analysis was performed using SPSS for Windows (SPSS Inc., Chicago, IL, USA).
Results

Study population
A total of 39 articles were selected for the analysis. All cases were either reported as single case reports or case series. There were no prospective or randomised trials found. A total of 88 neonates were included in our analysis, of which 60 (68.1%) were affected by congenital chylothorax and 28 (31.8%) by postoperative chylothorax (Tables 1-3 ). Among neonates with chylothorax following surgery, diaphragmatic hernia repair (13/28; 46.4%) and cardiac surgery (10/28; 35.7%) were the most common causes of postoperative chylothorax, while two patients were affected by iatrogenic chylothorax due to pleural drainage in one case and to superior vena cava thrombosis in the other. The remaining cases were secondary to oesophageal atresia (1/28; 3.6%) and thoracic surgery (2/28; 7.1%).
Subcutaneous octreotide regimen
Octreotide was predominantly administered as an intravenous infusion (84/88; 95.5%), although subcutaneous route of administration was also reported. Patients treated with subcutaneous injections of octreotide (4/88; 4.5%) were excluded from the main analysis and were reported separately (Table 1) . Treatment with octreotide was effective in all these patients without any reported adverse event. Treatment doses varied widely, from 1 to 70 μg/kg/ day, and the drug was administered from one to three times per day. Given the small number of cases, no formal statistical comparison between congenital and postoperative group was performed.
Intravenous octreotide regimen
Intravenous infusion of octreotide was administered to 84 of 88 neonates (95.5%), of whom 57 were affected by congenital chylothorax and 27 were affected by postoperative chylothorax (Tables 2 and 3 , respectively). Patients were treated with a continuous intravenous infusion in the majority of cases (82/84; 97.6%), while the remaining two patients in the case series of Bialkowski et al. 18 received the daily dose of octreotide in three divided intravenous boluses. Infants with congenital chylothorax showed a lower gestational age compared to infants with postoperative forms (mean 34.5 AE 3 vs. 36.9 AE 2.7; P = 0.001), while no differences in birthweight (mean 2820 AE 760 vs. 2754 AE 902; P = 0.89) and gender were found (P = 0.11).
The median initial dose of octreotide was 2 μg/kg/h (range 0.3; 15 μg/kg/h), and the median maximum dose was 7.5 μg/kg/h, ranging from 1 to 20 μg/kg/h (Table 4) , with a significant difference between congenital and postoperative cases for maximal dose (median 8.2, range 1-20 vs. 4, 1-15; P = 0.002) (Table 4) . However, a maximal dose higher than 10 μg/kg/h was reported in just 17 patients (19.3%). The median duration of octreotide therapy was 16 days, ranging from 1 to 47. In the case of postoperative chylothorax described by Cakir et al., 21 intravenous treatment lasted 16 days, and despite a quick clinical response, subsequent subcutaneous octreotide injections were administered for a total of 151 days.
In infants with congenital chylothorax, treatment duration in days was significantly longer (median 19, range 4-47 vs. 9.5, range 1-41; P = 0.002), and the maximum dose was significantly higher (median 10, range 1-20 vs. 4, range 1-15; P = 0.002) than in infants with postoperative chylothorax.
In most cases, treatment started with low doses of octreotide, and it was subsequently increased until a clinical response was reached. In two cases, a slight reduction in octreotide dose after drainage reduction was mentioned, but in all the other cases, treatment was maintained at the highest dose for several days after drainage cessation (Tables 2 and 3 ).
Octreotide efficacy
In our review, octreotide was considered effective if a progressive reduction/ceasing in drained chylous effusion occurred, irrespective of the time needed to reach this response. Time to observe the cessation of pleural effusion ranged from less than 3 days up to more than 28 days after treatment initiation, with a wide reduction of chylous effusion often occurring within the first few days of treatment. However, in 18 of 39 articles (46%), authors reported octreotide effectiveness or failure without further providing adjunctive information about the time needed to reach a clinical response (Tables 2 and 3) . We have to mention the paper by Scottoni et al. 33 who chose a punctual definition of octreotide treatment failure. It was defined as the persistence of chylous leak higher than 20 mL/ kg/day after 10 days of maximum dosing of intravenous octreotide or a daily drainage volume higher than 50 mL/kg/day while on intravenous octreotide. In addition, treatment duration before drainage cessation was extremely variable, as well as the time period defined by the authors to consider octreotide as effective. Overall, octreotide was effective in 39 patients (47%), without significant difference between congenital (53.6%) and acquired (33.3%) chylothorax (P = 0.10) ( Table 4) . When analysed by gestational age, no significant difference in efficacy was found between preterm and term infants (P = 0.4).
Side effects
Side effects were reported in 12 of 84 patients (14.2%) treated with intravenous infusion of octreotide (Tables 1-3) . Data on octreotide safety were not mentioned for 24 patients (28.6%). was considered according to a progressive reduction/ceasing in drained chylous effusion as stated by the authors. Time needed for drainage cessation is reported in brackets, if specified. Gestational age (GA) and treatment duration are expressed as median (if available) and range when more than one case is reported in the same article. -, Unreported data.
In the congenital group, the following adverse events were reported: hyperglycaemia (1/57, 1.7%), mild distended abdomen (1/57, 1.7%), transient mild cholestasis (1/57, 1.7%), transient hypothyroidism (1/57, 1.7%), bloody stools (1/57, 1.7%) and pulmonary hypertension (4/57, 7%). In neonates with postoperative chylothorax, one case of necrotising enterocolitis (NEC), one case of hyperglycaemia and elevation of liver enzymes and one case of severe hypotension were reported. Adverse events possibly related to octreotide use were observed in term and preterm infants regardless of chylothorax aetiology, with the most severe cases (NEC and severe hypotension) occurring in the postoperative forms. In addition, no association with octreotide dose and duration was observed (P = 0.35; P = 0.25, respectively). was considered according to a progressive reduction/ceasing in drained chylous effusion as stated by the authors. Time needed for drainage cessation is reported in brackets, if specified. Gestational age (GA) and treatment duration are expressed as median (if available) and range when more than one case is reported in the same article. NA, not applicable; SC, subcutaneous injections.
Discussion
Chylothorax remains a serious and potentially life-threatening disease in newborns, with no consensual agreement on the optimal treatment (Fig. 2) . 9 The use of octreotide in the conservative management of chylothorax in infants has been recently reviewed, but no clear indications on its efficacy, safety and optimal regimen have been identified, and no consistent recommendation on its use was reached. 10, 51, 52 Major limitations included the lack of uniformity in octreotide and somatostatin regimen, the small number of patients and the high variability of patient's characteristics and clinical conditions among studies. 10 After the first reports of chylothorax managed with somatostatin in adults 53 and infants, 54 its use in this condition became more widespread globally both for congenital and for acquired forms. Somatostatin is an endogenous polypeptide secreted by many organs, which acts as inhibitor on gastrointestinal tract secretions and on different endocrine systems. The mechanism of action of somatostatin in chylothorax is still uncertain. Somatostatin causes mild vasoconstriction in both arterial and lymphatic vasculature of the gut, lowering the hepatic venous flow. At the same time, it causes a reduction in gastric, pancreatic and bowel secretion. The consequent reduction of intestinal absorption may lead to a reduction in chylous flow. 55 Octreotide is a synthetic analogue of somatostatin that has recently replaced somatostatin for chylothorax treatment. Marked variation in the octreotide regimen among studies was observed, although the most common therapeutic scheme was an intravenous infusion at a starting dose of 1 μg/kg/h, gradually increasing to 10 μg/ kg/h according to the therapeutic response. Although higher maximum doses are reported, 10 μg/kg/h seems to be the threshold for was considered according to a progressive reduction/ceasing in drained chylous effusion as stated by the authors. Time needed for drainage cessation is reported in brackets, if specified. Gestational age (GA) and treatment duration are expressed as median (if available) and range when more than one case is reported in the same article. NA, not applicable; NEC, necrotising enterocolitis. increasing efficacy, while higher dosages do not seem to improve the clinical response. 56 In our review, we identified four case reports in which octreotide was administered via subcutaneous injections at 1-70 μg/kg/day, once daily or divided in three separate doses. In the majority of cases included in our review, octreotide was administered as a second-line treatment after total parenteral nutrition failure and before considering surgical pleurodesis. Octreotide was effective in 47% of the neonates included in our systematic review. We found that the maximum dose was similar in both non-responders and responders. This heterogeneity might be related to the diversity of underlying aetiologies. Our systematic review suggests that octreotide could be more effective in congenital chylothorax than in post-surgical chylothorax. At the same time, infants with the congenital forms were treated with higher dosages and for longer treatment periods. A possible explanation could be that pleural effusion may vary from nearly pure chylous lymphatic leakage to capillary transudation due to postoperative fluid overload. 1, 5 Therefore, differences in response to treatment with octreotide could be observed between these two groups. Most authors did not report pretreatment levels of pleural fluid triglycerides, so we could not consider it a factor affecting octreotide efficacy. Due to the large percentage of unreported data, few considerations about octreotide safety could be inferred from our analysis. Our study suggests that octreotide is safe, even at high doses and for long treatment periods. Side effects have been reported, but they seem to be related to individual susceptibility rather than to high dose or prolonged use. Scottoni et al. 33 reported a case of severe hypotension following intravenous octreotide administration, and a case of NEC was reported by Mohseni-Bod et al. 47 In both cases, infants were affected by postoperative chylothorax, hypothesising a specific vulnerability to vascular insults following cardio-thoracic surgery. Although based on few observations and considering the fragility of this population per se, it could be speculated that vasoconstriction and reduction of gut blood flow induced by somatostatin could increase the risk of complications in patients with vascular impairment, as in the case of cardiothoracic surgery. Pulmonary hypertension was reported in four of seven patients in Horvers et al.'s case series, 25 but it is not clear whether it was caused or maintained by octreotide treatment. Finally, the recent retrospective study of Church et al. 57 on the management of a large series of 178 infants affected by congenital and post-surgical chylothorax must be reported. They reviewed 45 patients receiving octreotide, and they found a 30% rate of NEC in preterm neonates treated with octreotide compared to just a 5% occurring in the general population, although this was not statistically significant (P = 0.09). The therapeutic regimen is not clearly specified in the article, but an intravenous infusion of octreotide at dose of 3 μg/kg/min (corresponding to 180 μg/kg/h) is reported in the article's discussion. We wrote to the J Pediatr Surg editor 58 with regard to this unusually high dosage, and Church replied 59 that 'We share his concern and wish to clarify that the reported octreotide infusion rate of 3 μg/kg/min in our paper should actually be 3 μg/kg/h'. Although the article by Church et al. 57 represents a large case series, we decided to exclude this paper from our analysis, concluding it as a possible confusing report.
As chylothorax is a very rare condition in newborns, our systematic review is based on single case reports and case series, while no prospective trials are currently available. Because of the rarity of this condition, reporting of cases could be fragmentary. In addition, the lack of uniformity in chylothorax aetiology and management, together with differences in octreotide administration and efficacy definition, could justify the poor accordance between studies. The major limitation of our study is that heterogeneous and scant definitions of octreotide efficacy were found among studies: in some cases, octreotide was judged effective if the response was noted after 2 or 3 weeks of drug administration, while it was considered ineffective after 3-10 days of treatment in others. In addition, few studies reported the rate of pleural drainage before and after starting octreotide, and a cut-off value for considering the treatment effective in terms of drainage reduction was rarely mentioned. Finally, in 18 of the 39 studies (46%) included in our review, the time threshold for establishing octreotide efficacy was not clearly specified. Considering the rarity of the disease and the lack of evidence on octreotide use, we chose not to limit our selection to studies providing a strict definition of octreotide efficacy; thus, studies in which efficacy was only stated by the authors were included.
Conclusion
Based on analysis of case reports and case series, octreotide appears to be a relatively effective and safe treatment option in neonates with chylothorax, especially for the congenital forms. Given the very low incidence and the heterogeneity of this condition in neonates, randomised controlled trials to clarify octreotide use appears to be quite unfeasible, even in multi-centric settings. Therefore, in order to elucidate an optimal regimen and therapeutic indications of octreotide while reporting cases of neonatal chylothorax, we suggest the inclusion of clear information about octreotide regimen, patient's demographic and clinical course, including an accurate report of pleural drainage modifications and time needed to observe it.
